Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Anthropic IPO Marketing Expected to Start in Mid-October 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Xiaomi Shares Jump on Europe EV Expansion Plan 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
JERSEY, Channel Islands, March 01, 2018 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cowen 38th Annual Global Health Care Conference on Tuesday, March 13th, 2018 at 8:00 a.m. EDT at The Boston Marriott Copley Place, in Boston, MA. The Company's Chief Financial Officer, Chris Lindop, will also be participating in the conference.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
